Ihsan Nijem

Charge variants in IgG1

Leslie A. Khawli, Sirj Goswami, Ryan Hutchinson et al. · mAbs · 2010 · 417 citations · Full text

Pharmacy, Pharmacokinetics, Pharmacology +17

Phase I Dose-Escalation Study of Onartuzumab as a Single Agent and in Combination with Bevacizumab in Patients with Advanced Solid Malignancies

Ravi Salgia, Premal H. Patel, John Bothos et al. · Clinical Cancer Research · 2014 · 65 citations · Full text

Medicine, Oncology, Pharmacology +17

Population pharmacokinetic analysis from phase I and phase II studies of the humanized monovalent antibody, onartuzumab (MetMAb), in patients with advanced solid tumors

Denise Jin, Stephen Eppler, Lisa A. Damico‐Beyer et al. · The Journal of Clinical Pharmacology · 2013 · 38 citations

Pharmacy, Oncology, Pharmacology +15

Development of a Subcutaneous Fixed‐Dose Combination of Pertuzumab and Trastuzumab: Results From the Phase Ib Dose‐Finding Study

Whitney P. Kirschbrown, Chris Wynne, Matts Kågedal et al. · The Journal of Clinical Pharmacology · 2018 · 37 citations · Full text

Medicine, Pharmacokinetics, Pharmacology +17

Onartuzumab (MetMAb): Using Nonclinical Pharmacokinetic and Concentration–Effect Data to Support Clinical Development

Hong Xiang, Brendan C. Bender, Arthur E. Reyes et al. · Clinical Cancer Research · 2013 · 35 citations · Full text

Pharmacy, Pharmacokinetics, Pharmacology +17